#001: The Watch Apple Has Been Promising Since Before the Watch Existed
A leadership change on Apple’s most elusive health project is the most quietly significant Apple story of the week, and it lands just days before WWDC, when Apple will talk about everything except this.
The Briefing:
Apple’s most important health project does not have a shipping date. It does not have a confirmed chip. It has not appeared in a single WWDC keynote. It has been in development, in some form, since before the first Apple Watch shipped in 2015, and reportedly since before Steve Jobs died in 2011. This week, Bloomberg’s Mark Gurman reported that Apple moved oversight of its noninvasive blood glucose monitoring project from platform architecture chief Tim Millet to Zongjian Chen, the engineering leader who runs Apple’s Advanced Technologies Group and was responsible for delivering the company’s in-house modem. Gurman’s framing was pointed: Chen is “known as someone who delivers.”
That sentence is doing a lot of work. The glucose project has cycled through leadership, produced proof-of-concept hardware that never shipped, and generated a decade of analyst predictions that were consistently wrong. It has also, quietly, remained one of the most consequential health technology problems anyone is trying to solve. More than half a billion people worldwide have diabetes. Noninvasive continuous monitoring, no needles, no separate device, just a wrist sensor would not just be an Apple Watch feature. It would be a meaningful public health tool at a scale no medical device has reached before.
The Chen transition does not mean a product is imminent. Gurman was careful about that, too. But the logic of the move is clear enough: Chen does not take things over to watch them stall. His track record suggests Apple has passed a threshold, moving from research-grade development toward something that could eventually be engineered into a consumer product. Whether that means Apple Watch Series 13, or Series 15, or never, cannot be determined from a leadership reassignment. But the person now responsible for the project has a different job description than the person who had it before. That matters.
In a week dominated by WWDC preview coverage, this was the story worth sitting with.
The documented length of Apple’s noninvasive glucose monitoring research program, predating the Apple Watch itself. Apple originally intended the first Apple Watch to launch with blood sugar sensing as a flagship health feature. It shipped in 2015 without it. A project this old, still active, still receiving new leadership rather than cancellation, is either Apple’s most persistent engineering failure or its most patient long-term bet. The Chen appointment suggests Apple has decided it is the latter.
What Apple's WWDC 2026 Will and Won’t Tell You
The June 8 keynote will be Apple’s most choreographed hour of the year. Here is what it structurally cannot show you.
WWDC keynotes are designed to generate developer confidence and consumer anticipation. They are not designed to surface work in progress, admit to previous shortcomings, or acknowledge projects that are not ready. iOS 27, by Bloomberg’s own reporting, is Apple’s “Snow Leopard” year, a release cycle built around fixing what shipped broken in iOS 26 rather than stacking new features on top of an unstable foundation. That framing is accurate and, if executed well, genuinely valuable. But it also means the keynote will be built around making refinement sound like ambition. The Siri redesign, a conversational interface with Dynamic Island integration and a dedicated app, will be presented as a leap forward. Whether it represents a leap forward from the Siri that currently exists, or merely from the Siri announced two years ago that never fully arrived, is a distinction the keynote will not draw.
WWDC on June 8 will tell you what Apple wants to ship this fall. It will not tell you whether the OpenAI partnership survives long enough to matter, whether the glucose project produces anything in this decade, or whether the Liquid Glass fixes on Mac are enough for the people who already decided Tahoe was a step backward. Those answers come later. The keynote is the opening argument.
Apple vs. the DOJ, Entering Its Most Complicated Phase
The antitrust case Apple has been fighting since 2024 just got harder to manage on both sides.
This week Apple filed a joint discovery dispute letter with the U.S. District Court for the District of New Jersey, asking a federal judge to compel the U.S. government to produce documents from 14 federal agencies that Apple argues are relevant to its defense. The government's position is that those documents do not need to be produced. This is pre-trial discovery maneuvering, not a turning point — but it illustrates where the case now sits. Two years in, both sides are still fighting over the evidentiary foundation rather than the substance. The DOJ's core allegation, that Apple illegally maintains a smartphone monopoly by restricting what developers and hardware partners can do within the iOS ecosystem, is still being argued at the procedural level. No trial date has been set. The case that could force Apple to structurally open its platform is grinding forward in the way cases of this scale actually grind: slowly, expensively, and largely invisible to the public until it suddenly is not.
- Oura Ring 5 ships June 4, and it moves into territory Apple Watch still hasn't reached. The fifth-generation ring announced this week is 40% smaller than the Ring 4, now measuring closer to a traditional band. The headline software addition is Health Radar, which continuously monitors biometric patterns for early signs of cardiovascular strain. Its Blood Pressure Signals feature tracks nighttime blood pressure trends and flags when patterns suggest increasing cardiovascular risk. It does not measure blood pressure directly, but it does something Apple Watch still cannot do at all. A Nighttime Breathing feature adds a rolling 30-day view of sleep-related breathing disturbances. Oura is also launching Health Records, letting U.S. users import diagnosed conditions, medications, and lab results directly into the app, and GLP-1 Insights for members tracking anti-obesity medications. Starts at $399.
- End-to-end encrypted RCS began rolling out in iOS beta on May 19. This closes the most significant security gap between iMessage and the cross-platform messaging standard Apple was required to adopt. It happened without a press release or keynote. Anyone still arguing that iMessage's privacy advantage is structural rather than strategic should update their position.
- OpenAI is still considering legal action against Apple and has not moved yet. Two weeks after Bloomberg reported that OpenAI had engaged outside legal counsel over the strained Siri partnership, no formal notice has been filed. OpenAI is managing the Musk vs. Altman trial simultaneously, which may explain the pace. The underlying dispute has not changed: ChatGPT was integrated so narrowly into Siri that the billions in subscription revenue OpenAI projected never materialized. The timeline for escalation has shifted. The facts of the dispute have not.
A new Beats FCC filing points to an unreleased over-ear device. No model name, no specs beyond what the filing requires. Beats has been dormant on the over-ear side since the Studio Pro. The filing lands ahead of a busy fall hardware cycle.
Zongjian Chen's track record on the modem. Before taking over the glucose project, Chen led Apple's years-long effort to replace Qualcomm modems with an in-house design. That project was also described as perpetually a few years away before it shipped in the iPhone 16e earlier this year. If the internal logic of the glucose reassignment follows the same pattern, Chen comes in when something is close enough to need a deliverer rather than a researcher — then the implied timeline shift matters. Watch for any signal in watchOS roadmap discussions at or after WWDC that health sensing hardware is receiving more engineering resources than prior years. That would be the next data point worth tracking.
Closing Thought:
Apple has a habit of treating its most consequential work as though it does not exist until the day it ships. The glucose project has been running longer than the Apple Watch product line. The DOJ case has been active for two years without a trial date. The OpenAI partnership has been deteriorating for months without a public acknowledgment. WWDC on June 8 will be polished, well-rehearsed, and genuinely interesting. It will also be the most visible layer of a company whose most important decisions are being made in engineering labs and federal courtrooms, not on a stage in Cupertino.
Of the three threads this week: glucose, antitrust, and OpenAI, which do you think has the most potential to change what an iPhone actually is five years from now?
Hit reply. I read every one.